Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 418 results for "erbitux"

Merck: Chinese Phase III Study With Erbitux Plus FOLFOX Meets Primary Endpoint
Nasdaq

Merck reports positive results form Chinese Phase III TAILOR t...

Merck has reported that the Chinese Phase III TAILOR study has demonstrated positive results of Erbitux (cetuximab) plus Folfox chemotherapy, compared with Folfox alone in patients with RAS wild-type metastatic colorectal cancer (mCRC). The ... Drug Development Technology, 3 days ago
[x]  

Medicare Looks To Cut Drug Costs By Changing How It Pays Doctors

Erbitux is used to treat cancers that start in the head and neck and tumors there that spread from other parts of the body. Because its effectiveness varies, should the price also? Dr. P. Marazzi/Science Source hide caption toggle caption Dr.
 NPR1 month ago
FOXNews.com

Motolimod Plus Cetuximab Proves Efficacious in Head and Neck Cancer

A neoadjuvant combination of motolimod (VTX2337) plus cetuximab (Erbitux) increases the immune responses in both the blood and tumor microenvironment for patients with head and neck squamous cell carcinoma (HNSCC). These factors help overcome ...
 Targeted Oncology2 months ago Merck and Bristol-Myers Squibb go head to head in cancer market  European Pharmaceutical Manufacturer16 hours ago Momentum Continues for Opdivo in Head and Neck Cancer  CURE Magazine4 days ago Opdivo Doubles One-Year Survival Rate in Head and Neck Cancer  CURE Magazine1 week ago
[x]  

Cetuximab Improves Long-Term Disease Control in HPV-Negative HNSCC

Adding cetuximab (Erbitux) to induction chemotherapy and hyperfractionated or accelerated chemoradiation therapy (CRT) produced long-term control for patients with HPV-negative, locoregionally advanced head and neck squamous cell carcinoma ...
 Targeted Oncology3 weeks ago

Global Erbitux Consumption Market Research Report 2016: Acute Market Reports

Acute Market Reports.com has announced the addition of "Erbitux Consumption Market Analysis And Segment Forecasts To 2016" Market Research report to their Database. The Global Erbitux Consumption 2016 Market Research Report is a professional and ...
 Press Release Ping1 month ago Mexico Erbitux Industry 2016 Market Research Report  MarketResearch.com1 month ago Europe Erbitux Market Research Report Policy Analysis 2021  Before It's News2 months ago LAMEA Oncology/Anti-cancer Drugs Market - Opportunities and Forecasts, 2014 - 2021  Research and Markets4 weeks ago

Antibodies in Oncology Drug Pipeline Update

The commercial and therapeutic success of antibodies like Rituxan, Avastin, and Erbitux will force the industry to look into the next generation of therapeutic antibodies, preparing themselves for the second wave in the lucrative field of ...
 Global Information Inc2 months ago

Oncobiologics on deck for IPO

Cranbury, NJ-based Oncobiologics (Pending: ONS ) is set for its IPO of 5M shares of common stock at $11 - 13. The clinical-stage biopharmaceutical firm develops biosimilars in immunology and oncology based on its proprietary BioSymphony Platform.
 Seeking Alpha7 hours ago

How Did Eli Lilly's 1Q16 Business Segment Perform?

What Drove Eli Lilly's 1Q16 Revenue Growth? ( Continued from Prior Part ) Performance by business segment Eli Lilly (LLY) is classified into two business segments: human pharmaceuticals and animal health. Over 84% of revenues come from the ...
 Yahoo! Finance UK and Ireland10 hours ago What Drove Eli Lilly's 1Q16 Earnings Growth?  Yahoo! Finance UK and Ireland1 day ago
[x]  

Bristol-Myers Squibb Reports First Quarter Financial Results

Press Release Apr 28, 2016 10:59 UTC NEW YORK--(Business Wire)-- Bristol-Myers Squibb Company (NYSE:BMY) today reported results for the first quarter of 2016, which were highlighted by strong sales for Opdivo , Eliquis and our hepatitis C ...
 Digital Journal1 day ago
[x]  

Patent Issued for Compounds and Methods for the Treatment of EGFR Positive Diseases (USPTO 9314536)

By a News Reporter-Staff News Editor at -- Bio-Thera Solutions, Ltd., Co. (Science City, CN) has been issued patent number 9314536, according to news reporting originating out of Alexandria, Virginia, by NewsRx editors (see also Bio-Thera Solutions, ...
 Equities.com1 day ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - erbitux
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less